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Abstract
Background: Advances in translational research have led to the need for well characterized
biospecimens for research. The National Mesothelioma Virtual Bank is an initiative which collects
annotated datasets relevant to human mesothelioma to develop an enterprising biospecimen
resource to fulfill researchers' need.
Methods: The National Mesothelioma Virtual Bank architecture is based on three major
components: (a) common data elements (based on College of American Pathologists protocol and
National North American Association of Central Cancer Registries standards), (b) clinical and
epidemiologic data annotation, and (c) data query tools. These tools work interoperably to
standardize the entire process of annotation. The National Mesothelioma Virtual Bank tool is based
upon the caTISSUE Clinical Annotation Engine, developed by the University of Pittsburgh in
cooperation with the Cancer Biomedical Informatics Grid™ (caBIG™, see http://cabig.nci.nih.gov).
This application provides a web-based system for annotating, importing and searching
mesothelioma cases. The underlying information model is constructed utilizing Unified Modeling
Language class diagrams, hierarchical relationships and Enterprise Architect software.
Result: The database provides researchers real-time access to richly annotated specimens and
integral information related to mesothelioma. The data disclosed is tightly regulated depending
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Conclusion: The National Mesothelioma Virtual Bank currently has over 600 annotated cases
available for researchers that include paraffin embedded tissues, tissue microarrays, serum and
genomic DNA. The National Mesothelioma Virtual Bank is a virtual biospecimen registry with
robust translational biomedical informatics support to facilitate basic science, clinical, and
translational research. Furthermore, it protects patient privacy by disclosing only de-identified
datasets to assure that biospecimens can be made accessible to researchers.
Background
The latest advancements in translational medicine
directed the path towards highly demanded biomarker
validation studies that focused on the identification of
new cancer biomarkers for cancer research community.
These studies lead toward the development of biobanks
that are capable of providing well annotated high quality
tissue samples that can meet the current demands of can-
cer research community. This objective is achieved suc-
cessfully by employing a well designed informatics
architecture that balances and supports the routine activi-
ties of a biobank [1]. Tissue Banking Informatics is rela-
tively novel area of biomedical informatics that deals with
collecting and storage of biospecimens with associated
clinicopathology annotation. The importance of the
development of tissue banks has been realized for the last
decade with the advent of advanced computer technology
that is utilized in the development of tissue bank infor-
matics infrastructure. These systems have the capability to
include the managing aspects of biobank that can func-
tion as central role in the development of translational
research initiatives [2-6].
National Mesothelioma Virtual Bank (NMVB), funded by
The Centers for Disease Control and Prevention (CDC) in
association with National Institutes of Occupational
Health and Safety (NIOSH), is an example of an excep-
tional and progressive tissue banking effort. The main
objective of this resource is to provide mesothelioma
pleural, pericardial and peritoneal tissue samples along
with blood and DNA samples with associated cancer reg-
istry, clinicopathology, recurrence and therapy related
data on a web based interface to meet the growing need of
cancer research community. The multimodal data is inte-
grated from various hospital systems into a web-based
architecture which is built upon a set of common data ele-
ments (CDEs) that provide semantic and syntactic inter-
operability across multiple institutions to facilitate
translation research. During the development of this
resource we applied the lessons learnt from the earlier col-
laborative projects: fundamental components and stand-
ards were employed from Cooperative Breast Cancer
Tissue Resource (CBCTR), Pennsylvania Cancer Alliance
Bioinformatics Consortium (PCABC), Cooperative Pros-
tate Cancer Tissue Resource (CPCTR), and the cancer Data
Standard Repository (caDSR) model of caBIG [6-11].
The manuscript highlights the infrastructure components
that were used to build this virtual biobank allowing it to
collect clinically annotated tissues from various clinical
settings which meet with statutory and best practice guide-
lines. This resource provides a web-based publicly accessi-
ble database that organizes the data by CDE standards and
allows the end users to query on de-identified informa-
tion within the warehouse through a controlled "point
and click" interface.
The resource also allows web-based requests for tissues,
provides a fair review process, delivers tissues to scientists,
permits growth and continual updates and integration
with other ongoing efforts, and markets the whole proc-
ess. Here we describe all the components that make up
this comprehensive NMVB informatics architecture, dis-
cuss the use of standards, and outline the previous collab-
orative biorepository experiences of the team at the
University of Pittsburgh, Department of Biomedical Infor-
matics [12].
Methods
Collaborative Institutions
The resource currently has three participating institutions:
University of Pennsylvania (U. Penn), University of Pitts-
burgh (U. Pitt) and New York University (NYU). The
other participants supporting this effort are the Mesothe-
lioma Applied Research Foundation (MARF), University
of Hawaii, University of Vermont, and Fox Chase Cancer
Center. The collaborative efforts make this resource capa-
ble of providing diverse biospecimens including fresh fro-
zen tissues, paraffin blocks, tissue microarrays (TMAs),
blood and DNA samples with clinicopathologic and fol-
low-up data from a wide variety of medical care settings
spread across rural and urban regions.
Inclusions/Exclusion Criteria of Cases into the Resource
Prospective Collection Criteria
The criteria for participation in the NMVB prospective
study is that the individuals are receiving or seeking med-
ical care for mesothelioma are 18 years old or older andPage 2 of 10
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either a doctor's office, clinic visits or upon hospital
admission.
The only exclusion criteria are patients younger than 18
years old and prisoner-patients, who are excluded based
on federal limitations. As very few patients are likely to
not be eligible for inclusion based on these criteria, the
racial, gender and ethnic characteristics of the individuals
approached for participation in this NMVB Registry reflect
the demographics of patients receiving or seeking medical
care at the mesothelioma clinics at the member institu-
tions of the consortium. No individuals are excluded from
participation in the NMVB Registry on the basis of race,
ethnicity, gender or HIV status.
Retrospective collection Criteria
The NMVB registry utilizes an honest broker system for
identifying and enrolling eligible retrospective cases into
the NMVB database. The honest broker system is also uti-
lized by the Tissue bank with Institutional Review Board
(IRB) approval for collecting excess tissue and biological
materials. The retrieval of samples from archived residual
biospecimens that have previously been removed for clin-
ical treatment and pathology diagnosis as well as retro-
spective review of associated medical records for
annotation purposes fall within the IRB's exempt category
[13].
Patient Health Information Protection and De-
Identification Process
The NMVB has designed its procedures to protect the con-
fidentiality and privacy of human subjects and IRB
approval has been obtained for all activities. NMVB uses a
decentralized system for specimen and data collection
and storage. Each case is assigned a de-identified NMVB
number. The only link to patient identity is held in reserve
locally within the institution and there are no links
directly connecting specimens or data to patients.
The NMVB database is available to the research commu-
nity on a public web site but it has been designed to pro-
duce only de-identified datasets upon query. This is
possible because only de-identified data sets exist which
are compliant with the 'safe harbour' approach to HIPPA
(Health Insurance Portability and Accountability Act)
[14]. The "safe-harbor" approach entails removal of all 18
identifiers enumerated at section 164.514(b) [2] of the
regulations. Thus for example, a participant's age is pre-
sented as age rage, rather than the date of birth, an
approach which protects the identity while still providing
sufficient information for research purposes. All data
requests are tracked in the secure NMVB web-based data
query tool regardless of whether the purpose is clinical or
research related.
The Honest Broker acts as a barrier between fully identi-
fied confidential clinical patient information and the
completely de-identified data made available to the
research community. An honest broker is an individual,
organization or system acting for or on behalf of the cov-
ered entity to collect and provide health information to
the investigators in such a manner whereby it would not
be reasonably possible for the investigators or others to
identify the corresponding patients-subjects directly or
indirectly. The honest broker cannot be one of the inves-
tigators or researcher. A researcher may use the services of
an honest broker service to obtain the Protected Health
Informations in a de-identified manner. De-identification
means that the patient-subjects cannot be identified by
researchers or others directly or indirectly through identi-
fiers link to the patient-subject. This honest broker service
will de-identify medical record information by automated
or manual methods. All honest broker services are
approved in advance by both the IRB of record and
UPMC. If an honest broker service is not part of the UPMC
covered entity, a valid business associate agreement with
UPMC is executed with UPMC in order to access UPMC-
held Protected Health Informations for de-identification.
If an honest broker system/service is to be used to obtain
de-identified Protected Health Informations, this fact
must be identified in the study's IRB submission. The
honest brokers are individuals who have clinical responsi-
bilities as tissue bankers in the Health Sciences Tissue
Bank (HSTB), postdoctoral fellows to manage the pathol-
ogy data or as cancer registry specialists in the UPMC Net-
work Cancer Registry. Based on their clinical job duties,
their educational backgrounds and experiences vary.
Depending on the nature of the projects, these bankers
can work autonomously or collaboratively to meet
biospecimen and/or data needs (please refer to additional
file 1) [13].
Development of the Common Data Elements
Common Data Elements were developed to allow annota-
tion of cases and accomplish characterization of biospec-
imens collected from different collaborating sites. The
development of CDEs for the resource has recently been
described in detail in a related publication from our group
[15]. In summary, the CDE development was by joint
consensus of participants (including domain experts from
various subcommittees) under the leadership supervision
of the NMVB Coordinating Committee. The CDEs include
cancer registry data (demographic, epidemiology and fol-
low-up) at the patient level, pathology data at the speci-
men level including data elements to elaborate TNM
staging and tumor grading, along with block level annota-
tion and genotype data [16]. In this process the CDE sub-
committee used the experiences gained from previous
projects like the PCABC [8], CPCTR [9], caBIG [11], Early
Detection Research Network (EDRN) [17] and SpecializedPage 3 of 10
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major standards used to develop the CDEs include the
NAACCR Data Standards for Cancer Registries [19], CAP
Cancer Protocol and Checklist [20], the ADASP – Associ-
ation of Directors of Anatomic and Surgical Pathology
(ADASP) [21] and the American Joint Committee on Can-
cer (AJCC) Cancer Staging Manual [22]. The utilization of
all the above mentioned standards facilitates the develop-
ment of CDEs that provides an informatics support which
is quite ample to achieve both syntactic and semantic
interoperability across various systems [15].
Data Collection and Method of Data Transmission
Retrospective Collection
Each collaborative site collects data and tissue samples.
Once a case becomes available the pathologists at each
site review the surgical pathology report and all histologi-
cal sections of the tissue facilitating the selection of the
mesothelioma case. Then the pathologist selects key
slides, referred to as matrix slides, according to a standard-
ized protocol with specific features of the case which is
likely to be of interest for scientific investigators. After-
wards the detailed data elements are collected on these
slides, and the slides are used to obtain the corresponding
matrix blocks which represent the core specimen compo-
nents of the Resource. This results in block-level annota-
tion of the case with recording of important information
about the case such as the size and type of tumor present
in each block of interest. Overall, this process increases the
utility of the resource many fold as the block level anno-
tation leads to finding cases queried by specific criteria at
a later point. This review up front also facilitates the
retrieval of such blocks when a request is received at a later
point. After the review of pathology data, the data manag-
ers and certified tumor registrars retrieve the clinical and
follow-up data for cases enrolled in the study. The data are
derived in part from the tumor registries of the various
hospitals and institutions, which include the Anatomic
Pathology Laboratory Information system (APLIS) (b)
Cancer Registry Information System (CRIS), and (c) Tis-
sue Banking Inventory System (TBIS).
Prospective Collection
To collect mesothelioma cases prospectively, patient are
being consented at the physician office or hospitals at
each collaborative site. At the time of patient enrollment
in the study prospectively a NMVB Health Assessment
Questionnaire is handed over to the patient. The purpose
of this questionnaire is to collect patient demographic,
epidemiology and past medical history data. Additionally,
detailed clinical information is obtained by direct review
of and extraction of information from patient charts, from
consultation with outpatient referring physicians, and
from direct patient interviews performed by cancer regis-
trars and clinical nurses. Data is collected and annotated
using common data entry paper forms that are correlated
with the CDEs developed by the Resource [12]. Finally,
collaborative sites transfer de-identified data to the central
database either manually using the web-based data entry
tool or electronically in spreadsheets.
Quality Assurance and Check of NMVB Datasets
The transmitted data from collaborative sites is reviewed
at the NMVB coordinating (database) site, which proc-
esses the data according to quality assurance (QA) and
quality check (QC) protocols every four months that has
been established by the resource. The process of QA/QC is
performed to locate any missing datasets and errors per-
formed during data recording. The value of each data set
is matched with the CDE dictionary to make certain the
standards are being followed during data recording. Only
the standardized data is uploaded into the database at reg-
ular basis, and data with errors is sent back to the corre-
sponding sites along with explanations of rejection. The
correction of the data is responsibility of each collabora-
tive site. To ensure the quality of data an audit review
process has been established.
The resource selects 20% of the newly entered cases to be
reevaluated by honest brokers, cancer registrars and data
managers. After completion of their review, the audit
reviewers submit a report of their findings and recom-
mendations to the resource. The resource members dis-
cuss their findings in the next general meeting of the
NMVB Coordinating Committee and make plans to
implement the proposed recommendations [12].
The NMVB resource has periodic QA/QC of pathology
data by assessing inter-observer concordance for the
resource pathologists. These consist of two methods
which include 1) the joint review of cases at meetings and
2) independent review of cases circulated among sites. For
joint QA review during meetings, resource pathologists
review up to 5 cases from each site, with emphasis on the
5 "matrix slides" selected by each pathologist at each site
to include areas of difficulty or likely diagnostic differ-
ences. Joint review of cases is performed on a multi-
headed microscope that permits pathologists to discuss
diagnostic differences and set thresholds.
Independent review of cases is performed by individual
pathologist at each site on cases sent from the other col-
laborative sites at regular intervals. The data mangers at
each site will randomly select the cases for QA review from
those added to the Resource within certain cut-off dates.
The review will be documented by completing the
"matrix" fields and select "histology" fields of the NMVB
database. Any areas that show a high level of discrepancy
will be determined by data mangers and communicated
to resource pathologists. The Pathology SubcommitteePage 4 of 10
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meeting of the Coordinating Committee and provide a
report with recommendations as indicated by their find-
ings [12].
Mesothelioma Virtual Bank Central Data Warehouse
The NMVB database is based on an informatics model
that aids in achieving semantic and syntectic interopera-
bility by describing the common data elements in the
form of metadata or data descriptors and by using a con-
trolled vocabulary in order to make the data understand-
able and sharable for end-users. The system architecture is
designed to provide query speed and high security as well
as expansion capabilities for incorporating new data ele-
ments or integrating existing systems at participating insti-
tutions. Emphasis has been placed to provide user access
at three levels (a) NMVB statistical data for public view (b)
approved investigator database query that allows seeing
individual patient de-identified clinical data and (c) data
manger access to query and edit the stored data. Patient
privacy is of utmost importance at all levels of user's
access.
The NMVB data warehouse is constructed using informa-
tion models captured as UML class diagrams. Unified
Modeling Language (UML) is a non-proprietary language
for constructing, visualizing, and documenting the arti-
facts of software engineering. The information model for
CDEs was created to establish a structurally aligned gener-
alized relationship [23]. Enterprise Architect (EA) soft-
ware has been utilized to develop the UML class diagrams
[24].
The NMVB web based query tool is based on the caTISSUE
Clinical Annotation Engine (CAE) application. CAE was
originally developed by the University of Pittsburgh as
part of the National Cancer Institute's (NCI) Cancer Bio-
medical Informatics Grid (caBIG) program [25]. The
NMVB database allows researches to search clinically
annotated Mesothelioma biospecimens via a web inter-
face in real time. The database is made available through
a publicly available website [26]. The database warehouse
facilitates standardized clinical annotation structure and
incorporates variety of data sets from different data
sources. Two methods of annotation have been adopted
manually using web based data entry tool and data
imported electronically through XML files [27].
Marketing of Resource Specimens
Various types of media resources are being utilized for the
advertisement of the NMVB biospecimens and services to
the research community as follow:
1. The NMVB web site has been developed and maintained
at Department of Biomedical Informatics at University of
Pittsburgh [28]. The web site includes general information
about the resource and different type of specimens availa-
ble to the research community.
2. Mass E- mailings to Investigator: Announcement letters of
invitation to utilize the resource are sent via e-mail to
investigators that have published articles in tissue- based
mesothelioma research. Additional names were provided
by investigators who visited the NMVB booth at scientific
meetings. A mechanism is provided for any email sub-
scriber to "opt out" from the mailing list at the time any
mass mailing is distributed.
3. Advertisements are placed in specialty scientific journals,
research society newsletters, fliers at research meetings,
and through free listings in journals and websites.
4. Posters and podium presentations regarding the practical
use and the Resource specimens at research meetings.
5. Marketing booths at scientific research meetings, in col-
laboration to CDC and NIOSH or as individual stan-
dalone booths. Marketing surveys were conducted at
scientific research meetings as well as with well-known
mesothelioma researchers to estimate what resources the
NMVB should focus on providing to the research investi-
gators.
Results
NMVB Biospecimens Collection
The NMVB resources hold over 650 archived mesotheli-
oma cases and prospective cases. The resource provides
more than 775 biospecimes that are accrued from surgical
resections and biopsies and also includes whole blood
and DNA samples.
This collection is made possible by the collaborative
efforts of University of Pennsylvania, University of Pitts-
burgh and New York University. At the end of second
quarter of 2008 we project the resource to have over 700
annotated cases of pleural, peritoneal and pericardial
mesothelioma specimens along with blood and DNA
samples available to the mesothelioma research commu-
nity. The majority of these cases consist of archival paraf-
fin blocks from surgically treated patients. In addition the
first Tissue Microarray (TMA) has been made available to
investigators along with de-identified clinicopathology
and follow-up data. IATA Dangerous Goods Regulations
[29] are implemented for the special handling and safe
shipping of biospecimen to investigators. All major cou-
rier companies acknowledge IATA measures of shipping
biohazardous supplies by air.
The NMVB common data elements (CDE) are developed
on NAACCR Data Standards for Cancer Registries [19],Page 5 of 10
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and the American Joint Committee on Cancer (AJCC)
Cancer Staging Manual [22] standards to build mesotheli-
oma CDE datasets. The NMVB web based Query Tool is
based upon CAE version 2.0. The query tool is secure pass-
word protected and only investigator by approved IRB
and Scientific Review Committee are capable to access the
database. It permits end-users to develop their own case
lists for their applications and quarry the data related to
the specimen cases they have received from the resource
for their approved studies. The query results shows only
de-identified datasets associated with each approved case
through disease and specimen pre-defined views of the
data set (Figure 1).
The NMVB Statistical Database for Public View is open to
the general public. The statistical data base for public
query provides summary information on all the mesothe-
lioma cases and their associated biospecimens stored into
biorespoitory. The result page shows the number of cases,
specimens and blocks in the database that match with
query criteria of the investigator and general statistics on a
limited number of data elements. By utilizing this public
view database the investigator could be able to gain
enough information to decide if the resource has suffi-
cient biospecimens to fulfill his experimental require-
ments (Figure 2).
Discussion
The growing importance of cross-institutional transla-
tional research and advancement in the development of
informatics tools that are capable of analyzing clinical tis-
sue sample has increased the need of research community
for high quality and well annotated biospecimens. To ful-
fill research community's requirements the NMVB has
established an integrated mesothelioma biobank and web
base database query tool. This system is built on an under-
lying architect of common data elements for characteriza-
tion of tissue samples and clinical follow-up data,
supported by an essential quality assurance process. By
Presents the NMVB approved investigator query toolFigure 1
Presents the NMVB approved investigator query tool. This view provides de-identified data sets upon end-user query.Page 6 of 10
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the resource developed a web based query tool to make
investigators knowledgeable of the resource biospeci-
mens. Finally, the NMVB resource has developed efforts to
market the specimens, and a process for requesting sam-
ples and data by investigators that involves an independ-
ent research evaluation panel (REP) of professionals on
mesothelioma, biostatistics, and pathology that are not
part of resource.
Clinical Annotation and development of federated Model 
NMVB datasets
The data mangers at each collaborative site are responsible
for clinical annotation of biospecimen and collect related
information manually from variety of data sources. The
collected data is then integrated, de-identified and stand-
ardized according to approved study protocols. The inte-
gration is a process in which a selected patient data is
collected from multiple clinical sources which includes
pathology data from the APLIS, tumor marker data from
the Clinical Pathology Lab Information System (CPLIS),
and clinical staging and treatment data from CRIS.
The challenges pertained to this process are identifying
the same patient across various hospital sources and col-
lecting the accurate data in precise context. These barriers
are overcome by common linking patient identifiers and
information and this helps in tracking the same patient
information across multiple sources. This also reduces the
chances of errors in data recording. The resource employs
this solution to address the challenges that are largely due
to a manual data collection and recording by the data
manger. This helps in keeping the focus only on data qual-
ity. The next challenge is to collect data that requires to be
monitored for context before it can be incorporated into
the database. This is important for the data that has tem-
poral relationship. The potential solutions to these chal-
lenges are automated data retrieval through electronic
Presents the NMVB statistical summary for public viewFigure 2
Presents the NMVB statistical summary for public view. This view provides overall statistics on all the cases and 
biospecimens stored into the resource.Page 7 of 10
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record (EMR) and cancer registry.
De-identification is the process which includes isolation
of patient clinical identified data sets that are kept in the
medical records from the research de-identified data sets.
This process is done by honest brokers who act as a barri-
cade between clinical identified data sets and totally de-
identified research data sets. The honest broker collects
clinical data, identifies the patient identifiers, separates
them by assigning the research de-identified number and
finally made de-identified data set available to research
community. The NMVB resources assign each case a 4-
digit de-identified case identification number and linkage
to the patient health information is kept by the honest
brokers. The NMVB database at no point in time present
any linkages to the patient identifiers (medical record
number, data of birth, social security number) to end
users.
To facilitate the standardized clinical annotation process
of biospecimens and to automate the process of annota-
tion, the NMVB project team incorporated the NAACCR
standard [19], CAP cancer protocol [20] and ADASP [21]
guidelines for mesothelioma as a well recognized, signifi-
cant and standardized sets of data elements in their
respective domain. These standards include a series of
reporting guidelines for diagnostic pathology reports and
outcome related descriptors for the vast majority of
human malignancies. Each CAP guideline is comprised of
checklists with the data elements to describe the gross as
well as microscopic attributes of the neoplasm including
pathological staging and perifocal reactions such as mar-
gins, angio- as well as perineural invasion with specified
valid values for each data element that are important for
clinical decision-making and prognostication of individ-
ual cases.
The process of developing the CDEs for the NMVB has
authenticated this initiative that can successfully direct to
the implementation of strong human mesothelioma-
related CDEs that assist in the collection of high quality
data for the research community. The CDE are developed
by NMVB CDE subcommittee that included experts from
various clinical and research fields e.g. pathologists, tho-
racic surgeons, epidemiologists, bioinformaticians,
biostatisticians, data managers, cancer registrars, and
research scientists.
Finally the purpose was to create datasets that should pro-
vide value to the end users in future. Furthermore, the def-
initions of the CDEs and their associated descriptors need
to be clearly understandable to all those who collects data.
Through the use of ISO compliance and accepted data
standards the goal of collecting annotation data of high
quality was achievable. The only way in which informa-
tion from multiple databases can truly be shared and
made useful is through the careful use of unequivocal,
well defined, consistent and structured metadata. Infor-
maticians and database developers provided the structural
link that brought the CDEs together in the database,
addressed technical issues, and provided guidance related
to implementation of the CDEs at local institutions.
Presentation of NMVB Web Base Query Tool
The CAE model enables standards-based manual annota-
tion of biospecimens with associated well-characterized
clinical information. It supports importing structured
data from various clinical information systems such as
APLIS, CPLIS and cancer tumor registries allowing the
integration of multimodal annotations within the cancer
centers, providing a complete picture of a patient's disease
[12]. Additionally, the CAE is based on such a model that
aids in developing and conveying the semantic interoper-
ability of the data system by describing the common data
elements in the form of metadata or data descriptors
(about the content, quality, condition, and other charac-
teristics of the data) and by using controlled vocabulary
and ontology, in order to make the data understandable
and sharable for end-users and flexible for the system.
Hence, the overall advantage of this suite over the legacy
biospecimen annotation systems includes the shared
responsibilities of individual institutions for services and
implementation of the required standards and vocabulary
that fosters data sharing effortlessly.
Conclusion
The NMVB stands as a nation wide largest resource for
mesothelioma archived and prospective biosepcimens
with associated clinical, pathology, recurrence, follow-up
and treatment data and act as a central resource for inves-
tigators using experimental methods in translational, his-
topathology, validation and outcomes measures. This
resource is built upon a robust and efficient informatics
architecture that facilitates well organized management,
standardized collection and detailed clinical annotation
of cases across multiple collaborative sites. This set-up
provides a manual of operation, a histopathology guide,
and a database with common data elements for character-
ization of mesothelioma biospecimens, multimodal data-
sets and a quality assurance and control process.
The NMVB web based query tool acts as a central source
that provides a mechanism for researchers to efficiently
search clinically annotated datasets and biospecimens
that are pertinent to their research areas. The web-based
query tool ensures patient health information protection
by disclosing only de-identified data with Institutional
Review Board (IRB) and scientific review committee
approved standards and protocols. Additionally NMVBPage 8 of 10
(page number not for citation purposes)
BMC Cancer 2008, 8:236 http://www.biomedcentral.com/1471-2407/8/236web site facilitates an online process of requesting mes-
othelioma biospecimen, acces statistical query tool for
public view and access to approved investigator query tool
to potential investigator. The biospecimens disbursement
and database access to patient de-identified clinical data is
granted after Research Evaluation Panel (REP) approval
that includes experts on mesothelioma, biostatics and
pathology. Different methods are adopted to market the
resource that includes brochures, a website, and a booth
that is being used to market the resource at scientific meet-
ings. In fact NMVB presents as a fundamental platform for
the development and implementation of an integrated tis-
sue banking program and facilitates other tissue banking
efforts through the members of the collaborative resource
and their associated publications.
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